



Jan

PATENT
Customer No. 22,852
Attorney Docket No. 2356.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Pierre DRUILHE) Group Art Unit: Not assigned
)
Application No.: 10/691,672) Examiner: Not assigned
)
Filed: November 12, 2003)
)
For: GLURP-MSP3 FUSION PROTEIN,)
IMMUNOGENIC COMPOSITIONS)
AND MALARIAL VACCINES)
CONTAINING IT)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

This paper supplements the Information Disclosure Statement filed February 26, 2004. Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached IDS Form PTO/SB/08. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

The attached documents were cited in the International Search Report in the corresponding PCT application No. PCT/EP02/012910.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: April 26, 2005

By: 

Kenneth J. Meyers
Reg. No. 25,146
Phone: 202-408-4033
Fax: 202-408-4400

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Application Number</i>	10/691,672
(Use as many sheets as necessary)				<i>Filing Date</i>	November 12, 2003
				<i>First Named Inventor</i>	Pierre Druilhe
				<i>Art Unit</i>	1653
				<i>Examiner Name</i>	Not assigned
				<i>Attorney Docket Number</i>	02356.0085
Sheet	1	of	1		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		WO 02/092628 A2	11.21.92	Pierre Druilhe		
		WO 2004/043488 A1	5.27.04	Theisen et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		International Search Report for corresponding PCT application No. PCT/EP02/012910	
		Theisen et al.; A plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies; Internet Article Online (October 2003) pp. 1-17.	
		Theisen et al.; A plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies; <i>Vaccine</i> , Vol. 22, No. 9 (March 2004) pp. 1188-1198	
		Carvalho et al.; IM-95 Immunization of saimiri sciureus monkeys with MSP-3 and GLURP, two plasmodium falciparum antigens targets of protective antibodies; <i>Mem do Instituto Oswaldo Cruz</i> , Vol. 94, No. 11 (November 1999) pg. 216	
		Carvalho et al.; Malaria vaccine: candidate antigens, mechanisms, constraints and prospects, <i>Scand. J. Immunol.</i> , Vol. 56 (2002) pp. 327-343	
		Bredmose et al.; Development of a heterologous gene expression system for use in lactococcus lactis, <i>Recombinant Protein Production with Prokaryotic and Eukaryotic Cells</i> , pp. (2001) 269-275	
		Theisen et al.; The glutamate-rich protein (GLURP) of plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth <i>in vitro</i> ; <i>Infection and Immunity</i> , Vol. 66, No. 1 (January 1998) pp. 11-17	
		Theisen et al.; Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein; <i>Infection and Immunity</i> , Vol. 72, No. 1 (January 2004) pp. 247-252	
		Carvalho et al; Immunization of saimiri sciureus monkeys with plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels; <i>Scandinavian Journal of Immunology</i> , Vol. 59, No. 4 (April 2004) pp. 363-372	

Examiner Signature	Date Considered
-----------------------	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.